Skip to main content

IDENTIFICACION DE NUEVAS DIANAS TERAPEUTICAS PARA EL TRATAMIENTO DEL FENOTIPO MOLECULAR HER2-ENRICHED EN CANCER DE MAMA RECEPTOR HORMONAL POSITIVO

PI19/01846

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • Adam-Artigues, Anna|||0000-0002-4257-8535
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Cervera Vidal, Raimundo|||0000-0002-8213-4058
  • Tormo, Eduardo
  • Hernando Davalillo, Cristina
  • Martínez Martínez, María Teresa|||0000-0003-1312-3555
  • Carbonell Asins, Juan Antonio|||0000-0002-8449-5674
  • Simón, Soraya
  • Poveda Ferriols, Jesús Manuel|||0000-0002-9785-0997
  • Moragón, Santiago|||0000-0001-6490-6977
  • Zazo, Sandra
  • Martínez, Débora
  • Rovira, Ana|||0000-0003-1301-2599
  • Burgués, Octavio|||0000-0002-2471-5516
  • Rojo, Federico|||0000-0001-9989-0290
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Bermejo, Begoña
  • Lluch, Ana|||0000-0003-2766-407X
  • Prat, Aleix|||0000-0003-2377-540X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Eroles, Pilar|||0000-0003-2708-6206
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer. AXL is a prognostic biomarker and a potential therapeutic target to restore trastuzumab response in HER2 + breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

  • Prat, Aleix|||0000-0003-2377-540X
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Martínez-Sáez, Olga|||0000-0001-8686-0236
  • Sanfeliu, Esther|||0000-0002-7974-3346
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Galván, Patricia
  • Martínez, Débora
  • Pascual, Tomás|||0000-0001-8431-3183
  • Marín Aguilera, Mercedes
  • Rodríguez, Anna
  • Chic, Nuria
  • Adamo, Barbara
  • Paré Brunet, Laia
  • Vidal Losada, Maria|||0000-0003-1992-5727
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Felip, Eudald|||0000-0002-3812-1313
  • Matito, Judit|||0000-0001-7560-7737
  • Sánchez-Bayona, Rodrigo
  • Suñol Camas, Anna
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ciruelos, Eva|||0000-0002-2796-1042
  • Tolosa, Pablo|||0000-0002-3747-4766
  • Muñoz, Montserrat
  • González Farré, Blanca|||0000-0002-1796-7248
  • Villagrasa, Patricia
  • Parker, Joel S.
  • Perou, Charles M.|||0000-0001-9827-2247
  • Vivancos, Ana|||0000-0003-2888-6512
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0.5X shallow whole-genome sequencing in plasma from 459 patients with metastatic breast cancer, including 245 patients treated with endocrine therapy and a CDK4/6 inhibitor (ET + CDK4/6i) from 2 independent cohorts. We demonstrate that machine learning multi-gene signatures, obtained from ctDNA, identify complex biological features, including measures of tumor proliferation and estrogen receptor signaling, similar to what is accomplished using direct tumor tissue DNA or RNA profiling. More importantly, 4 DNA-based subtypes, and a ctDNA-based genomic signature tracking retinoblastoma loss-of-heterozygosity, are significantly associated with poor response and survival outcome following ET + CDK4/6i, independently of plasma tumor fraction. Our approach opens opportunities for the discovery of additional multi-feature genomic predictors coming from ctDNA in breast cancer and other cancer-types. Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer

  • Palafox, Marta|||0000-0002-1762-3250
  • Monserrat, Laia|||0000-0002-8802-3033
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ibrahimi, Nusaibah|||0000-0003-4537-0323
  • Kannan, Srinivasaraghavan|||0000-0002-9539-5249
  • Mina, Leonardo
  • Herrera-Abreu, Maria Teresa
  • Òdena, Andreu|||0000-0003-1529-880X
  • Sánchez Guixé, Mònica|||0000-0002-9430-4413
  • Capelán, Marta
  • Azaro, Analía
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Grueso, Judit|||0000-0003-1093-7940
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Su, Faye
  • Lin, Kui
  • Clarke, Robert B.|||0000-0001-5407-3123
  • Caldas, Carlos|||0000-0003-3547-1489
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Michiels, Stefan|||0000-0002-6963-2968
  • García-Sanz, Alicia
  • Turner, Nicholas C.|||0000-0001-8937-0873
  • Prat, Aleix|||0000-0003-2377-540X
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Verma, Chandra S.
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Arnedos, Monica
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Serra, Violeta|||0000-0001-6620-1065
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.